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Abstract
L-Lysine monohydrochloride is a feed additive produced by fermentation using a genetically modiﬁed
strain of Escherichia coli (CGMCC 7.57). The Panel on Additives and Products or Substances used in
Animal Feed (FEEDAP Panel) of the EFSA, in its opinion on the safety and efﬁcacy of the product,
could not conclude on the safety of the product for target animals, consumers, users and the
environment. The European Commission asked EFSA to deliver an opinion on the safety of L-lysine
monohydrochloride as a nutritional additive for all animal species based on additional data submitted
by the applicant on the characterisation of the additive. No recombinant antibiotic resistance genes are
present in the production strain and therefore in the ﬁnal product. The L-lysine monohydrochloride
manufactured by fermentation using E. coli CGMCC 7.57 does not raise safety concerns for the target
species, consumers, users and the environment with regard to the genetic modiﬁcation of the
production strain. The levels of endotoxins present in the product and its dusting potential indicate no
health risk for the user.
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Summary
Following a request from the European Commission, the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on L-lysine
monohydrochloride produced by a genetically modiﬁed strain of Escherichia coli (CGMCC 7.57) for all
animal species.
In 2015, the FEEDAP Panel of the European Food Safety Authority (EFSA) adopted an opinion on
the safety and efﬁcacy of L-lysine monohydrocloride produced by fermentation using E. coli CGMCC
7.57. In that opinion, the FEEDAP Panel could not conclude on the safety of the product for target
animals, consumers, users and the environment.
The applicant provided additional information in relation to the characterisation of the additive and
the production process. The FEEDAP Panel has performed the assessment of those new data following
an approach in line with the principles laid down in Regulation (EC) No 429/2008 and the relevant
guidance documents.
This product was characterised in a previous scientiﬁc opinion (EFSA FEEDAP Panel, 2015).
No recombinant antibiotic resistance genes are present in the production strain and therefore in the
ﬁnal product. The L-lysine monohydrochloride manufactured by fermentation using E. coli CGMCC 7.57
does not raise safety concerns for the target species, consumers, users and the environment with
regard to the genetic modiﬁcations of the production strain.
The levels of endotoxins present in the product and its dusting potential indicate no health risk for
the user.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1831/2003 establishes rules governing the Community authorisation of additives
for animal nutrition and, in particular, Article 9 deﬁnes the terms of the authorisation by the
Commission.
The applicant, Feedway Europe NV, is seeking a Community authorisation of L-lysine
monohydrochloride (HCl) produced by fermentation with Escherichia coli to be used as a nutritional
additive for all animal species. (Table 1)
On 10 March 2015, the Panel on Additives and Products or Substances used in Animal Feed
(FEEDAP Panel) of the European Food Safety Authority, in its opinion on the safety and efﬁcacy of the
product, could not conclude on the safety of the product L-lysine HCl produced by fermentation with
this recombinant E. coli strain for target animals, consumers, users and the environment. Regardless
of the assessment of the genetic modiﬁcation, the FEEDAP Panel has concerns regarding the safety of
the simultaneous oral administration of the product L-lysine HCl via water for drinking and feed.
FEEDAP Panel has concerns that the safety of the genetic modiﬁcation may also have implications for
the safety of the user.
The Commission gave the possibility to the applicant to submit complementary information to
complete the assessment on the safety and to allow a revision of Authority’s opinion.
The Commission has now received new data on the safety of L-lysine monohydrochloride produced
by Escherichia coli.
In view of the above, the Commission asks the Authority to deliver a new opinion on the safety of
L-lysine monohydrochloride produced by fermentation with Escherichia coli as nutritional additive for all
animal species based on the additional data submitted by the applicant.
1.2. Additional information
L-Lysine monohydrochloride (minimum content of L-lysine 78%, ‘as is’ basis) was ﬁrst authorised for
use in animal nutrition by Directive 88/485/EEC. It is currently included in the European Union as a
nutritional additive (functional group amino acids, their salts and analogues) for use in all animal
species without time limit and without maximum content in feed.
The applicant has provided additional information on the physical properties of the additive, the
characterisation of the genetic modiﬁcation and on the production process.
Although the additive was initially intended to be used in all animal species as a nutritional additive
(functional group amino acids, their salts and analogues) in feed and water for drinking, during the
assessment the applicant requested to withdraw the use of the additive in water for drinking.1
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier2 following a previous application on the same product.3
Table 1: Description of the substances
Category of additive Nutritional additive
Functional group of additive Amino acids, their salts and analogues
Description L-Lysine in the form of L-lysine monohydrochloride (HCl),
technically pure
Target animal category All animal species
Applicant Feedway Europe NV
Type of request New opinion
1 Technical dossier/Correspondence and mandate/FAD-2015-0030 withdrawal partial app to EC and EFSA 150416.
2 FEED dossier reference: FAD-2015-0030.
3 FEED dossier reference: FAD-2010-0281.
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2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the characterisation and safety of L-lysine
monohydrochloride (HCl) produced by E. coli CGMCC 7.57 is in line with the principles laid down in
Regulation (EC) No 429/20084 and the relevant guidance documents: Guidance on nutritional additives
(EFSA FEEDAP Panel, 2012a), Guidance on studies concerning the safety of use of the additive for
users/workers (EFSA FEEDAP Panel, 2012b) and Guidance on the risk assessment of genetically
modiﬁed microorganisms and their products intended for food and feed use (EFSA GMO Panel, 2011).
3. Assessment
The current application is for the authorisation of L-Lysine monohydrochloride produced by a
genetically modiﬁed (GM) strain of E. coli (CGMCC 7.57) which is a derivative of E. coli K-12. It is
intended to be used in all animal species as a nutritional additive (functional group amino acids, their
salts and analogues) in feed.
3.1. Characterisation
This product has been characterised in a previous scientiﬁc opinion (EFSA FEEDAP Panel, 2015)
with the exception of the genetic modiﬁcation, for which the absence of antibiotic resistance genes in
the production strain (and therefore in the product) was insufﬁciently proven.
Additional data have been submitted on the genetic modiﬁcation process of the production strain,
the physico-chemical properties of the additive and on its manufacturing process.
3.1.1. Impurities
The endotoxin activity in the former product (three batches analysed) ranged from 6.3 to
6.6 IU/mg.5 An improvement in the manufacturing has been introduced in the downstream process to
reduce the amount of bacterial endotoxins in the ﬁnal product. The ﬁltration by ceramic membrane
has been modiﬁed (from a former pore size of 300 kDa to the current smaller size of 20 kDa) and
reverse osmosis has been applied to reduce the amount of endotoxins in the process water.6 New data
have been submitted on the bacterial endotoxin activity of the product, measured in three batches.
The values ranged from 0.12 to 0.28 IU/mg (European Pharmacopoeia 2.6.14 methods).7
3.1.2. Physical properties
The applicant stated that the production process had been modiﬁed to increase the crystal size of
the ﬁnal product and consequently decrease its dustiness. The evaporation temperature has been
lowered (75–72°C), the evaporation rate reduced (2.5–2.0 m3/h), the evaporation time prolonged
(12–15 h) and the cooling time extended from 3 to 5 h.8
New analytical data have been provided to characterise the particle size and dustiness of the new ﬁnal
product. The particle size distribution (three batches analysed by laser diffraction) had a fraction of
particles < 50 lm of diameter ranging from 0.2% to 1.2% (v/v) (mean particle diameter is about
600 lm).9 In the former product (ﬁve batches analysed, method unknown), about 2.3% (w/w) of particles
had a diameter < 50 lm.10 The dusting potential (three batches analysed by the Stauber–Heubach
method) ranged from 1.3 to 1.6 g/m3.11 The dusting potential of the product assessed in 2015 (three
batches) ranged from 1.8 to 2.1 g/m3.12
4 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
5 Technical dossier FAD-2010-0281/Supplementary information January 2013/Attachment 19.
6 Technical dossier/Supplementary information March 2016/Attachment 2.
7 Technical dossier/Technology improvement on production process, Supplementary information on endotoxin levels and
Attachments 1–3.
8 Technical dossier/Technology improvement on production process.
9 Technical dossier/Supplementary information March 2016/Attachments 5 and 6.
10 Technical dossier FAD-2010-0281/Section II.5 and Annex II.1.2.
11 Technical dossier/Supplementary information March 2016/Attachment 5.
12 Technical dossier FAD-2010-0281/Supplementary information May 2014/Reply 4/Attachment 7.
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3.1.3. Characterisation of the production strain E. coli CGMCC 7.5713
In the former assessment of the production strain (EFSA FEEDAP Panel, 2015), no conclusive
evidence was provided regarding the absence of antibiotic resistance genes (transiently used in the
genetic modiﬁcation) in the genome of the production strain or in the product.
The applicant has now provided analyses indicating that those genes are not present in the
production strain.14
3.2. Safety
In its previous assessment (EFSA FEEDAP Panel, 2015), the FEEDAP Panel could not conclude on
the safety of the product L-lysine HCl produced by fermentation with this recombinant E. coli strain for
target animals, consumers, users and the environment because the genetic modiﬁcation, including the
presence or absence of antibiotic resistance genes in the production strain (and therefore in the
product), was insufﬁciently characterised.
The applicant has provided evidence that the production strain does not carry the antibiotic
resistance genes transiently used during the genetic modiﬁcation. Absence in the product of
recombinant DNA corresponding to the inserted sequences was previously shown (EFSA FEEDAP
Panel, 2015). Therefore, L-lysine monohydrochloride manufactured by fermentation with E. coli CGMCC
7.57 does not raise any safety concern for the target animals, consumers, users and the environment
with regard to the genetic modiﬁcation of the production strain.
3.2.1. Safety for the user
In the previous opinion (EFSA FEEDAP Panel, 2015), it was concluded that there was no concern
for users with respect to skin or eye irritancy and dermal sensitisation. Nevertheless, the level of
endotoxins present in the product and its dusting potential indicated an inhalation risk for the user.
The concerns on the safety of the genetic modiﬁcation may also have implications on safety for the
user.
3.2.1.1. Effects on the respiratory system
Although a previous assessment was performed in March 2015 (EFSA FEEDAP Panel, 2015),
technological improvement in the manufacturing process makes it necessary to reassess the safety for
the user when exposed by inhalation to the bacterial endotoxin activities found in the additive.
The bacterial endotoxin activity (the three new batches) ranges from 0.12 to 0.28 IU/mg.15 The
dusting potential ranges from 1.3 to 1.6 g/m3.16
The scenario used to estimate the exposure of persons handling the additive to endotoxins in the
dust, based on the EFSA Guidance on user safety (2012b) is described in Appendix A. The health-
based recommended threshold for the quantity of inhaled endotoxins per working day is 900 IU,
derived from provisional occupational exposure limits given by the Dutch Expert Committee on
Occupational Safety (DECOS) (Health Council of the Netherlands, 2010) and the UK Health and Safety
Executive (HSE, 2013). Based on the calculation of the potential endotoxin content in dust (Wallace
et al., 2016), the inhalation exposure could be up to 246 endotoxin IU per 8-h working day, indicating
no risk from the exposure to endotoxins for people handling the additive.
3.2.1.2. Conclusions on safety for the user
The additive L-lysine monohydrochloride is not a skin or eye irritant nor a skin sensitiser. The levels
of endotoxins present in the product and its dusting potential indicate no health risk for the user.
4. Conclusions
No recombinant antibiotic resistance genes are present in the production strain and therefore in the
ﬁnal product. The L-lysine monohydrochloride manufactured by fermentation using E. coli CGMCC 7.57
13 This section has been amended following the applicable provisions on conﬁdentiality.
14 Technical dossier/Supplementary information March 2016/Attachment 1 Lysine HCl detection of antibiotic-resistant genes.
15 Technical dossier/Supplementary information on endotoxin levels and Attachments 1–3.
16 Technical dossier/Supplementary information March 2016/Attachment 5.
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does not raise safety concerns for the target species, consumers, users and the environment with
regard to the genetic modiﬁcation of the production strain.
The levels of endotoxins present in the product and its dusting potential indicate no health risk for
the user.
Documentation provided to EFSA
1) Dossier L-lysine in the form of L-lysine monohydrochloride, technically pure. October 2015.
Submitted by Feedway Europe NV/Meihua Holdings Group Co., Ltd.
2) Dossier L-lysine in the form of L-lysine monohydrochloride, technically pure. Supplementary
information. November 2015. Submitted by Feedway Europe NV.
3) Dossier L-lysine in the form of L-lysine monohydrochloride, technically pure. Supplementary
information. March 2016. Submitted by Feedway Europe NV.
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CGMCC China General Microbiological Culture Collection Centre
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EC European Commission
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GMO EFSA Panel on Genetically Modiﬁed Organisms
HCl monohydrochloride
HSE British Health Safety Executive
IU International unit of endotoxin activity. One IU corresponds to one endotoxin unit (EU)
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Appendix A – Safety for the user
The effects of endotoxin inhalation and the exposure limits have been described in a previous
opinion (EFSA FEEDAP Panel, 2015).
Calculation of maximum acceptable levels of exposure from feed additives
The probable exposure time according to EFSA guidance (EFSA FEEDAP Panel, 2012b) for additives
added in premixtures assumes a maximum of 40 periods of exposure per day, each comprising 20 s,
equal to 800 s/day. With an uncertainty factor of 2, the maximum inhalation exposure would occur for
2 9 800 s = 1,600 s (0.444 h/day). Again, assuming a respiration volume of 1.25 m3/h, the inhalation
volume providing exposure to potentially endotoxin-containing dust would be 0.444 9
1.25 = 0.556 m3/day. This volume should contain no more than 900 IU endotoxin, so the dust formed
from the product should contain no more than 900/0.556 = 1,619 IU/m3.
Calculation of endotoxin content of dust
Two key measurements are required to evaluate the potential respiratory hazard associated with the
endotoxin content of the product (the dusting potential of the product, expressed in g/m3, and the
endotoxin activity of the dust, determined by the Limulus amoebocyte lysate assay (expressed in
IU/g)).17 If data for the dust are not available, the content of endotoxins of the product can be taken
instead. If the content of endotoxins of the relevant additive is a IU/g and the dusting potential is b
g/m3, then the content of endotoxins of the dust in the air, c IU/m3, is obtained by simple multiplication,
a 9 b. This resulting value is further used for calculation of the potential inhalatory exposure of users to
endotoxins from the additive under assessment (Table A.1) (EFSA FEEDAP Panel, 2012b).
Table A.1: Estimation of user exposure to endotoxins from the additive L-lysine HCl produced by
Escherichia coli CGMCC 7.57, including consideration of using ﬁlter half mask (FFP2 or
FFP3)(a) as a preventive measure
Calculation Identiﬁer Description Amount Source
a Endotoxin content IU/g product 280 Technical dossier
b Dusting potential (g/m3) 1.58 Technical dossier
a 9 b c Endotoxin content in the air (IU/m3) 442
d No. premixture batches made/working day 40 EFSA FEEDAP
Panel (2012b)
e Time of exposure (s) per production of one batch 20 EFSA FEEDAP
Panel (2012b)
d 9 e f Total duration of daily exposure/worker (s) 800
g Uncertainty factor 2 EFSA FEEDAP
Panel (2012b)
f 9 g h Reﬁned total duration of daily exposure/worker (s) 1,600
h/3 600 i Reﬁned total duration of daily exposure (h) 0.44
j Inhaled air (m3) per 8-h working day 10 EFSA FEEDAP
Panel (2012b)
j/8 9 i k Inhaled air during exposure (m3) 0.56
c 9 k l Endotoxin inhaled during exposure per 8-h working day 246
m Health-based recommended exposure limit
of endotoxin (IU/m3) per 8-h working day
90 Health Council of the
Netherlands (2010)
m 9 j n Health-based recommended exposure limit of total
endotoxin exposure (IU) per 8-h working day
900
l/10 Endotoxins inhaled (IU) per 8-h working day
reduced by ﬁlter half mask FFP2 (reduction factor 10)
25
l/20 Endotoxins inhaled (IU) per 8-h working day
reduced by ﬁlter half mask FFP3 (reduction factor 20)
12
(a): Filtering face piece or ﬁltering half mask according to European standard EN 149. They are graded from 1 to 3 depending on
their ﬁltering capacity.
17 The Limulus amebocyte lysate is an aqueous extract of circulating amebocytes from the horseshoe crab (Limulus polyphemus).
This extract reacts with minute quantities of bacterial endotoxin (lipopolysaccharide from the walls of Gram-negative bacteria)
and this reaction is the basis of the assay used for the detection and quantiﬁcation of bacterial endotoxins.
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